Founded in 1929, it is a time-honored brand in China, a large-scale enterprise integrating the cultivation and processing of medicinal materials, the research and development of natural medicines and health products, the production and sales of modern dosage forms of traditional Chinese medicine and health foods

Lanzhou Foci Pharmaceutical Co., Ltd. is a municipal state-controlled listed company with a pharmaceutical history of nearly 100 years and a "China Time-honored Brand" enterprise (stock code 002644). It was founded in Shanghai in 1929. In 1956, he moved west to Lanzhou. Launched in 2011. At present, the company has developed into a backbone enterprise in the traditional Chinese medicine industry in Northwest China, which integrates the cultivation and processing of medicinal materials, the research and development of natural medicines and health products, the production and sales of modern dosage forms of traditional Chinese medicine and health foods.

Up to now, the company has 4 production bases, 1 medical science and technology industrial park under construction and 3 wholly-owned subsidiaries. It has total assets of 100912 million yuan and net assets of 718.23 million yuan. There are more than 1,400 employees, including more than 400 engineering and technical personnel. It has 25 production lines, all of which have passed the national GMP certification, and the production lines of the headquarters have also passed the certification of the Australian TGA organization, the Japanese Ministry of Health and Welfare and the Ukrainian Product Certification Agency. At present, there are 345 drug production approval numbers, 10 exclusive products such as Dingdizzy Pills and Ginseng Guben Pills, 1 national protected variety of traditional Chinese medicine, 9 invention patents, and 152 kinds of Chinese and Western medicine products in 11 dosage forms such as concentrated pills, big honey pills and tablets all year round. Foci products are well-known at home and abroad for their "authentic materials, excellent craftsmanship, exact curative effect, and convenient taking". "Foci" brand Liuwei Dihuang Pill, Qiju Dihuang Pill, Guifu Dihuang Pill, Xiaoyao Pill, Xiangsha Stomach Pill and other series of products have been rated as "Gansu Famous Brand Products" for many times. The company's product field continues to expand, and the big health products represented by Ejiao and Materia Medica drink "Xiao Assistant" have been launched one after another. The "Minshan" trademark is a key protected trademark of the State Administration for Industry and Commerce, and "Baolu" and "Shanshu" are famous trademarks in Gansu Province. The company has established good cooperative relations with many first-class scientific research institutes at home and abroad, such as China Academy of Chinese Medical Sciences, Stockholm University in Sweden, Tsinghua University, Gansu University of Traditional Chinese Medicine, etc. At present, there are two key R&D platforms in Gansu Province: the Engineering Technology Research Center for Modern Chinese Medicine Preparations and the Sino-Swiss Natural Plant Medicine and Health Products Research Center. In Zhangxian, Lintan and other places, there are standardized planting bases of Angelica sinensis, with a total planting area of nearly 10,000 acres. Foci brand at home and abroad has a good market foundation and extensive influence, the international and domestic sales network is increasingly perfect, the products are sold throughout the country, exported to the United States, Australia, Japan, Hong Kong and other 27 countries and regions, the number of foreign certifications, overseas trademark registration, export coverage, export varieties have long been in the forefront of the industry. Foci Pharmaceutical is the first company in China to apply for EU drug registration, if the concentrated Angelica pill is successfully registered in the EU and passes the EU GMP certification, Foci products are expected to enter the EU market as a drug, and at the same time establish the international standard of traditional Chinese medicine. Recently, Foci Pharmaceutical has been included in the list of "the first batch of backbone enterprises for Chinese medicine service trade" by the Ministry of Commerce and other ministries and commissions.

In the past three years, the company will rely on the new area project, focus on building an international and domestic sales network, seize opportunities, accelerate development, and strive to achieve an operating income of 1 billion yuan within three years, of which the export of Chinese patent medicine is 10 million US dollars.